Gowri Sivaramakrishnan1, Kannan Sridharan2. 1. 1Department of Oral Health, College of Medicine, Nursing and Health Sciences, Fiji National University, Brown Street, Suva, Fiji. 2. 2Department of Health Sciences, Fiji National University, Extension Street, Suva, Fiji.
Abstract
BACKGROUND: Serratiopeptidase for pain, facial swelling and trismus associated with surgical removal of impacted molar is under investigation. However conclusive evidence on the use of serratiopeptidase is lacking. Hence a systematic review and meta-analysis of randomized controlled studies was carried out. METHODS: Electronic databases were searched for eligible studies and necessary data extracted. The data were analysed using non-Cochrane mode in RevMan 5.0. 95% confidence interval (95% CI) was used to represent the deviation from the point estimate. The heterogeneity between the studies was assessed using Forest plot visually, I2 statistics and Chi square test with a statistical P value of <0.10 to indicate statistical significance. Random-effect models were used in case of moderate to severe heterogeneity. RESULTS: Five studies were included for final review. Serratiopeptidase improved trismus better than corticosteroids with the MD, 95% as 4.42 [3.84, 5]. As regards to swelling, no significant difference was observed for serratiopeptidase when compared to corticosteroids. Paucity of studies precludes any conclusion for other outcome measures as well as for other comparator drugs. CONCLUSION: Serratiopeptidase could be used safely and effectively to improve trismus and facial swelling after surgical removal of impacted molar.
BACKGROUND: Serratiopeptidase for pain, facial swelling and trismus associated with surgical removal of impacted molar is under investigation. However conclusive evidence on the use of serratiopeptidase is lacking. Hence a systematic review and meta-analysis of randomized controlled studies was carried out. METHODS: Electronic databases were searched for eligible studies and necessary data extracted. The data were analysed using non-Cochrane mode in RevMan 5.0. 95% confidence interval (95% CI) was used to represent the deviation from the point estimate. The heterogeneity between the studies was assessed using Forest plot visually, I2 statistics and Chi square test with a statistical P value of <0.10 to indicate statistical significance. Random-effect models were used in case of moderate to severe heterogeneity. RESULTS: Five studies were included for final review. Serratiopeptidase improved trismus better than corticosteroids with the MD, 95% as 4.42 [3.84, 5]. As regards to swelling, no significant difference was observed for serratiopeptidase when compared to corticosteroids. Paucity of studies precludes any conclusion for other outcome measures as well as for other comparator drugs. CONCLUSION: Serratiopeptidase could be used safely and effectively to improve trismus and facial swelling after surgical removal of impacted molar.
Authors: David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza Journal: BMJ Date: 2004-06-19
Authors: A Mazzone; M Catalani; M Costanzo; A Drusian; A Mandoli; S Russo; E Guarini; G Vesperini Journal: J Int Med Res Date: 1990 Sep-Oct Impact factor: 1.671
Authors: L Selan; R Papa; M Tilotta; G Vrenna; A Carpentieri; A Amoresano; P Pucci; M Artini Journal: BMC Microbiol Date: 2015-10-09 Impact factor: 3.605
Authors: Zaid Tamimi; Rola Al Habashneh; Islam Hamad; Mutasim Al-Ghazawi; Ala' Abu Roqa'a; Hamza Kharashgeh Journal: BMC Oral Health Date: 2021-03-02 Impact factor: 2.757